In the last trading session, 1.35 million shares of the Syndax Pharmaceuticals Inc (NASDAQ:SNDX) were traded, and its beta was 0.86. Most recently the company’s share price was $11.33, and it changed around $0.09 or 0.80% from the last close, which brings the market valuation of the company to $974.87M. SNDX currently trades at a discount to its 52-week high of $25.07, offering almost -121.27% off that amount. The share price’s 52-week low was $9.66, which indicates that the current value has risen by an impressive 14.74% since then. We note from Syndax Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 2.27 million shares, with the 3-month average coming to 2.17 million.
Syndax Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.23. If we narrow it down even further, the data shows that 0 out of 15 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 1 recommended SNDX as a Hold, whereas 10 deemed it a Buy, and 0 rated it as Underweight. Syndax Pharmaceuticals Inc is expected to report earnings per share of -1.28 for the current quarter.
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) trade information
Instantly SNDX has showed a green trend with a performance of 0.80% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 11.84 on recent trading dayincreased the stock’s daily price by 4.31%. The company’s shares are currently down -14.30% year-to-date, but still up 7.29% over the last five days. On the other hand, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) is -13.11% down in the 30-day period. We can see from the shorts that 19.36 million shares have been sold at a short interest cover period of 10.46 day(s).
The consensus price target as assigned by Wall Street analysts is $27.5, which translates to bulls needing to increase their stock price by 58.8% from its current value. Analyst projections state that SNDX is forecast to be at a low of $18 and a high of $37.
Syndax Pharmaceuticals Inc (SNDX) estimates and forecasts
The year-over-year growth rate is expected to be 258.06%, up from the previous year.
Consensus estimates provided by 10 financial analysts predict the company will bring in an average of 15.06M in revenue for the current quarter. 9 analysts expect Syndax Pharmaceuticals Inc to make 17.79M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 408.31%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -15.16%. Syndax Pharmaceuticals Inc earnings are expected to increase by -3.79% in 2025, but the outlook is positive 26.50% per year for the next five years.
SNDX Dividends
Syndax Pharmaceuticals Inc’s next quarterly earnings report is expected to be released on 2025-Mar-02.
Syndax Pharmaceuticals Inc (NASDAQ:SNDX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.26% of Syndax Pharmaceuticals Inc shares, and 116.10% of them are in the hands of institutional investors. The stock currently has a share float of 117.58%. Syndax Pharmaceuticals Inc stock is held by 291.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 9.2721% of the shares, which is about 7.91 million shares worth $162.33 million.
WELLINGTON MANAGEMENT GROUP LLP, with 8.6063% or 7.34 million shares worth $150.67 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Jan 31, 2025 . The former held 2.99 shares worth $33.85 million, making up 3.47% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 2.55 shares worth around $28.92 million, which represents about 2.97% of the total shares outstanding.
